Apollo Hospitals has delivered a robust performance for the third quarter of the 2025-26 fiscal year, showcasing double-digit growth across its primary business verticals. The Chennai-based healthcare major reported a 35% year-on-year surge in consolidated net profit, reaching 502 crore. Revenue for the quarter grew by 17%, climbing to 6,477 crore compared to 5,527 crore in the previous year. This growth was driven by a strong showing in healthcare services and a significant turnaround in the digital and pharmacy segments. The core Healthcare Services division remains the primary engine of growth, contributing 3,183 crore in revenue, a 14% increase. Operational efficiency in this segment reached a high note with EBITDA margins expanding to 24.8%. This performance was supported by a 67% occupancy rate across its facilities and an increase in high-end surgical volumes. Apollo HealthCo, which includes the pharmacy distribution and the Apollo 24/7 digital platform, reported a 20% increase in revenue to 2,827 crore. Notably, its EBITDA more than doubled to 128 crore as the company successfully optimized its digital health spending. The segment's net profit rose sharply to 87 crore from 32 crore a year earlier. The retail and diagnostic arm, Apollo Health and Lifestyle, also saw a 20% revenue jump to 467 crore. The segment significantly narrowed its losses to 6 crore, moving closer to the break-even point through improved scale and operating leverage across its clinic network. Reflecting this financial strength, the Board of Directors declared an interim dividend of 10 per share. The record date for this payout is fixed for February 16, 2026. Strategic expansion remains a key priority. During the quarter, the company launched a new 250-bed quaternary care hospital in Pune, equipped with advanced surgical robotics and precision oncology tools. Apollo is currently on track to add over 3,500 beds across 11 locations over the next few years. Market analysts maintain a positive outlook on the stock. Citi has reiterated a Buy rating with a target price of 9,600, citing the company's clinical depth and the value-unlocking potential of its digital restructuring. Currently, the stock trades near 7,220, reflecting a market capitalization of approximately 1,03,800 crore. This performance aligns with broader trends in the Indian healthcare sector, which is projected to reach 638 billion USD by 2025. Rising medical tourism and a domestic shift toward organized tertiary care continue to provide strong tailwinds for integrated providers like Apollo.